Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-22

Clinical Trial Update: A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating CC-90011 in combination with nivolumab in advanced cancers have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CC-90011
  • nivolumab (nivolumab)

Snippet

Sponsor: Celgene | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2025-01-22